Director/PDMR Shareholding

e-Therapeutics plc

Director/PDMR Shareholding

e-Therapeutics plc (AIM: ETX), the drug discovery and development company with a proprietary platform in network pharmacology, announces that on 8th November 2012 Professor Malcolm Young, CEO, purchased 20,000 shares at 33.5 pence per share for his Self-Invested Personal Pension Fund. Following this purchase, Professor Young's direct beneficial interest is 21,043,630 ordinary shares, representing 15.23% of the total issued share capital of the Company. Professor Young's indirect holding remains 403,148 shares, representing 0.29% of the total issued share capital of the Company.

-Ends-

For more information, please contact:

e-Therapeutics plc

Malcolm Young / Daniel Elger

Tel: +44 (0) 7909 915 068

www.etherapeutics.co.uk 

Panmure Gordon (UK) Limited

Fred Walsh / Hannah Woodley / Grishma Patel

Tel: +44 (0) 20 7886 2500

www.panmure.com

College Hill

Melanie Toyne Sewell / Jayne Crook

Tel: +44 (0) 20 7457 2020

Email: e-therapeutics@collegehill.com

CommStrat Group (US)

Ted Agne

Tel: (+1) 781 631 3117

Email: edagne@comstratgroup.com